

Please revise the claims as follows:

--1. (currently amended) A method of monitoring whether an animal that has received a transplanted kidney has is ~~experiencing~~ a kidney disease involving smooth muscle cell abnormalities, the method comprising:

analyzing a sample taken from the animal for the ~~degree of~~ presence of a marker protein selected from the group consisting of:

(a) phosphorylated protein ~~proteins~~ having a sequence of ~~at least 95 percent homology to phosphorylated SEQ. ID NO. 1 in a form comprising in which phosphorylated tyrosine; at least a tyrosine of SEQ. ID NO. 1 has been phosphorylated;~~

(b) phosphorylated protein ~~proteins~~ having a sequence of ~~at least 95 percent homology to phosphorylated SEQ. ID NO. 2 in a form comprising in which phosphorylated tyrosine; at least a tyrosine of SEQ. ID NO. 2 has been phosphorylated;~~

(c) ~~proteins~~ protein having a sequence of ~~at least 95 percent homology to~~ SEQ. ID NO. 1; and

(d) ~~proteins~~ protein having a sequence of ~~at least 95 percent homology to~~ SEQ. ID NO. 2;

wherein the disease is kidney transplant rejection; and

wherein the analyzing comprises:

contacting the sample or materials derived therefrom with a means of perceiving the marker protein; and

either:

(i) comparing the amount of marker protein so perceived with the amount of marker protein in a known standard to diagnose whether the animal has such a disease; or

(ii) attempting to visualize the marker protein to diagnose whether the animal has such a disease.

2. (previously presented) The method of claim 1, wherein the animal is a primate.

3. (canceled)

4. (currently amended) The method of claim 2 ~~claim 3~~, wherein the method further comprises examining protein fragments solubilized from a homogenate of the sample for the presence of a fragment of the selected marker protein ~~which is between 20 kDa and 80 kDa in size.~~

5. (currently amended) The method of claim 1, wherein the marker protein is SEQ. ID NO. 1 in a form in which at least a tyrosine of SEQ. ID NO. 1 has been phosphorylated.

6. (currently amended) A method of monitoring whether a ~~transplant selected from the group consisting of~~ transplanted kidney organs, transplanted tissues, and transplanted cells is being rejected by an animal recipient of the transplant, comprising:

analyzing a sample taken from the recipient for the ~~degree of~~ presence of a marker protein selected from the group consisting of:

(a) phosphorylated protein ~~proteins~~ having a sequence of at least 95 percent homology to phosphorylated SEQ. ID NO. 1 in a form comprising in which phosphorylated tyrosine at least a tyrosine of SEQ. ID NO. 1 has been phosphorylated;

(b) phosphorylated protein ~~proteins~~ having a sequence of at least 95 percent homology to phosphorylated SEQ. ID NO. 2 in a form comprising in which phosphorylated tyrosine; at least a tyrosine of SEQ. ID NO. 2 has been phosphorylated;

(c) ~~proteins~~ protein having a sequence of at least 95 percent homology to SEQ. ID NO. 1; and

(d) ~~proteins~~ protein having a sequence of at least 95 percent homology to SEQ. ID NO. 2;

wherein the analyzing comprises:

contacting the sample or materials derived therefrom with a means of perceiving the marker protein; and

either:

(i) comparing the amount of marker protein so perceived with the amount of marker protein in a known standard to diagnose whether the animal has such a disease; or

(ii) attempting to visualize the marker protein to diagnose whether the animal has such a disease.

7. (currently amended) The method of claim 6, wherein the method comprises examining protein fragments solubilized from a homogenate of the sample for the presence of a fragment of the selected marker protein ~~which is between 20 kDa and 80 kDa in size.~~

8. (original) The method of claim 6, wherein the animal is a primate.

9. (original) The method of claim 8, wherein the animal is a human.

10. (canceled)

11. (canceled)

12. (original) The method of claim 6, wherein the sample is a portion of a transplanted kidney.

13. (currently amended) The method of claim 6, wherein the marker protein is SEQ. ID NO. 1 in a form in which at least a

tyrosine of SEQ. ID NO. 1 has been phosphorylated.

14. (withdrawn) A phosphorylated protein fragment in a form isolated from other proteins having a size greater than 100 kDa, wherein the protein is between 20 and 80 kDa in size and is selected from the group consisting of a fragment of phosphorylated SEQ. ID NO. 1 in a form in which at least a tyrosine of SEQ. ID NO. 1 has been phosphorylated and a fragment of phosphorylated SEQ. ID NO. 2 in a form in which at least a tyrosine of SEQ. ID NO. 2 has been phosphorylated.

15. (withdrawn) An antibody capable of binding to at least two of the claim 1 proteins, at least one of which is not phosphorylated, and at least one of which is phosphorylated.

16. (withdrawn) A kit for monitoring whether an animal is experiencing a disease and/or adverse condition involving smooth muscle cell abnormalities, the kit comprising a claim 15 antibody.--